title: New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
abstract: Despite availability of standardized drug therapies with proven beneficial outcomes, heart failure is associated with poor quality of life, increased hospital readmission, and high mortality rate. In the recent years, comprehensive understanding of the pathophysiological mechanisms of heart failure has led to the development and approval of 2 new pharmacological agents, sacubitril-valsartan and ivabradine. These agents are currently approved for use in heart failure with reduced ejection fraction (HFrEF) and present as novel approaches to further improve prognosis and outcomes in patients with HF. They offer alternative treatment options for patients who are intolerant or continue to be symptomatic despite utilization of standard HF drug therapies at optimally tolerated dosages. A review of these 2 novel agents in HFrEF, including information on pivotal trials that led to its approval and its place in therapy for HFrEF, is presented.
authors.affiliation: 1 Pharmacy Practice, Touro College of Pharmacy, New York, NY, USA.
authors.forename: Shreya
authors.initials: S
authors.lastname: Patel
authors.affiliation: 1 Pharmacy Practice, Touro College of Pharmacy, New York, NY, USA.
authors.forename: Keith
authors.initials: K
authors.lastname: Veltri
mesh_terms: D000613:Aminobutyrates / Q000494:pharmacology / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000077550:Ivabradine; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D013318:Stroke Volume / Q000187:drug effects* / Q000502:physiology; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001552:Benzazepines; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents; D004338:Drug Combinations; D013777:Tetrazoles; D000077550:Ivabradine; D000068756:Valsartan; C549068:sacubitril and valsartan sodium hydrate drug combination
keywords: heart failure with reduced ejection fraction; ivabradine; neprilysin inhibitor; sacubitril-valsartan; selective If inhibitor